𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Experimental results of a self-adaptive integrated control system in buildings: a pilot study

✍ Scribed by A Guillemin; N Morel

Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
138 KB
Volume
72
Category
Article
ISSN
0038-092X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Comprehensive Experimental Study of Ae
A Comprehensive Experimental Study of Aerial Pollutants in and Emissions from Livestock Buildings. Part 2: Results
✍ T. Hinz; S. Linke πŸ“‚ Article πŸ“… 1998 πŸ› Elsevier Science 🌐 English βš– 521 KB

Comprehensive measurements of aerial pollutants were carried out in a mechanically-ventilated fattening piggery and in a naturally-ventilated (Louisiana-type) broiler house. In the piggery, ventilation rate was directly measured using fan-wheel anemometers and indirectly estimated by a CO balance me

Single session educational programme for
Single session educational programme for caregivers of psychogeriatric in-patients – results from a randomised controlled pilot study
✍ Eivind Aakhus; Knut Engedal; Tom Aspelund; Geir SelbΓ¦k πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 1 views

## Abstract ## Background Family caregivers of patients with psychiatric or medical disorders are at risk of developing psychological distress. Studies including family caregivers of patients with dementia have shown that psychoeducative programmes reduce distress and postpone institutionalisation

Imatinib in active diffuse cutaneous sys
Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center
✍ Janet Pope; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Faye πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 60 KB πŸ‘ 2 views

## Abstract ## Objective To better understand the feasibility of using imatinib, a tyrosine kinase inhibitor, to treat active diffuse cutaneous systemic sclerosis (dcSSc). ## Methods We performed a 6‐month, randomized, double‐blind, placebo‐controlled, proof‐of‐concept pilot study of imatinib in